Supporting Data for "Two-Headed Trojan Horses: Bimetallic Pt(IV)/Ga(III) Drugs as Efficient and Safe Dual Action Broad Spectrum Antibiotics"

Abstract

This data includes all primary data gathered from various instrumentation which we reported in Wagner et al. Two-Headed Trojan Horses: Bimetallic Pt(IV)/Ga(III) Drugs as Efficient and Safe Dual Action Broad Spectrum Antibiotics. In Wagner et al. we found: A strategy to develop novel broad-spectrum antibiotics is to redirect current anticancer agents to bacteria via the use of a targeting vector that simultaneously increases the uptake of the drug by bacteria while limiting their cytotoxicity on mammalian cells. This strategy is rendered more powerful if the targeting vector also has an antimicrobial effect achieved via a different mechanism of action such as gallium. The platinum-based anticancer drug carboplatin is redirected to bacteria via conjugation of its Pt(IV) analog to deferoxamine, a siderophore. The bimetallic Ga(III)-Pt(IV) conjugates displayed substantial and broad inhibition of bacterial growth of both gram-negative and gram-positive bacteria, including resistant strains, and is more effective than either component alone. Importantly, the complexes have negligible cytotoxicity against HEK 293. Altogether, bimetallic Ga(III)/Pt(IV) conjugates are effective dual-action antibiotic with a broad-spectrum effect and the potential to combat antibiotic resistance while minimizing cytotoxicity toward mammalian cells.